CINECA IRIS Institutional Research Information System

TRUSOLINO, Livio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.394
AS - Asia 10.920
EU - Europa 10.467
OC - Oceania 280
SA - Sud America 233
AF - Africa 85
Continente sconosciuto - Info sul continente non disponibili 16
Totale 37.395
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.918
CN - Cina 6.394
IT - Italia 2.869
GB - Regno Unito 1.284
DE - Germania 1.229
JP - Giappone 1.108
SG - Singapore 968
FR - Francia 820
IE - Irlanda 676
SE - Svezia 539
ES - Italia 511
FI - Finlandia 496
KR - Corea 477
IN - India 462
HK - Hong Kong 426
CA - Canada 395
NL - Olanda 309
UA - Ucraina 259
PL - Polonia 229
TW - Taiwan 218
AU - Australia 213
CH - Svizzera 211
BE - Belgio 202
BR - Brasile 159
TR - Turchia 154
AT - Austria 151
VN - Vietnam 131
ID - Indonesia 128
RU - Federazione Russa 103
IL - Israele 100
GR - Grecia 95
TH - Thailandia 83
PT - Portogallo 81
CZ - Repubblica Ceca 74
DK - Danimarca 72
MX - Messico 67
NZ - Nuova Zelanda 67
RO - Romania 59
IR - Iran 58
NO - Norvegia 49
HU - Ungheria 36
SA - Arabia Saudita 31
PK - Pakistan 30
MY - Malesia 29
EG - Egitto 26
CO - Colombia 23
CL - Cile 19
AR - Argentina 17
ZA - Sudafrica 16
HR - Croazia 14
JO - Giordania 14
LB - Libano 14
MO - Macao, regione amministrativa speciale della Cina 14
SK - Slovacchia (Repubblica Slovacca) 14
PH - Filippine 13
UZ - Uzbekistan 13
LT - Lituania 12
NG - Nigeria 12
QA - Qatar 11
AM - Armenia 10
RS - Serbia 10
SI - Slovenia 10
EE - Estonia 9
PE - Perù 9
SN - Senegal 9
LU - Lussemburgo 8
AP - ???statistics.table.value.countryCode.AP??? 7
BA - Bosnia-Erzegovina 7
EU - Europa 7
KE - Kenya 7
TN - Tunisia 7
CY - Cipro 6
AE - Emirati Arabi Uniti 5
EC - Ecuador 5
IS - Islanda 5
KZ - Kazakistan 5
BG - Bulgaria 4
BY - Bielorussia 4
CU - Cuba 4
GE - Georgia 4
LK - Sri Lanka 4
OM - Oman 4
PR - Porto Rico 4
IM - Isola di Man 3
KH - Cambogia 3
MK - Macedonia 3
MT - Malta 3
PA - Panama 3
A1 - Anonimo 2
AD - Andorra 2
AL - Albania 2
DM - Dominica 2
DZ - Algeria 2
MA - Marocco 2
BD - Bangladesh 1
BN - Brunei Darussalam 1
GH - Ghana 1
GL - Groenlandia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
Totale 37.389
Salva come PNG Salva come JPEG
Città #
Beijing 1.338
Chandler 1.118
Ann Arbor 1.049
Shanghai 948
Fairfield 843
Singapore 722
Houston 667
Dublin 627
Redwood City 556
Santa Clara 536
Ashburn 508
Guangzhou 454
Seattle 443
Cambridge 416
Woodbridge 408
Wilmington 402
Torino 380
Tokyo 336
Nanjing 270
Milan 268
Dearborn 240
Turin 240
New York 225
Jacksonville 200
Nyköping 193
Villeurbanne 193
Hangzhou 191
Columbus 189
Princeton 188
Boston 173
Wuhan 170
Medford 169
Pisa 162
San Diego 151
Warsaw 150
Lappeenranta 146
Los Angeles 142
London 139
Chengdu 127
Taipei 126
Rome 115
Vienna 114
Zhengzhou 111
Jakarta 108
Paris 107
Fremont 106
Changsha 96
Toronto 89
Naples 88
Duncan 87
Boardman 86
Central 85
Barcelona 84
Munich 84
San Francisco 84
Helsinki 82
Chicago 81
Brussels 80
Seoul 77
Ottawa 76
Dong Ket 75
Madrid 73
Amsterdam 72
Central District 70
Jinan 70
Shenyang 67
Berlin 66
Chongqing 64
Manchester 64
Tianjin 63
Nanchang 60
Norwalk 58
Shenzhen 52
Genoa 51
Hong Kong 50
Fuzhou 49
Mumbai 49
Hefei 48
Philadelphia 45
San Jose 42
Sydney 42
Heidelberg 41
São Paulo 41
Carrara 40
Xian 40
Bangkok 39
Dallas 39
Osaka 39
Atlanta 35
Melbourne 35
Toulouse 35
Vancouver 35
Washington 35
Baltimore 34
Istanbul 34
Phoenix 34
Bengaluru 33
Florence 33
Pittsburgh 33
Nashville 32
Totale 19.560
Salva come PNG Salva come JPEG
Nome #
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. 5.344
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 5.231
Stromal contribution to the colorectal cancer transcriptome. 1.908
Adaptive mutability of colorectal cancers in response to targeted therapies 1.894
MET signalling: principles and functions in development, organ regeneration and cancer. 1.604
Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy 1.596
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.166
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. 737
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 674
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 669
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 575
Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer 418
The genomic landscape of response to EGFR blockade in colorectal cancer 358
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. 348
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer 342
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 337
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. 323
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 321
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 282
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 258
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 257
Only a subset of Met-activated pathways are required to sustain oncogene addiction 252
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 251
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment 250
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype 248
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations 247
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. 227
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis 224
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 221
Inhibition of Src impairs the growth of met-addicted gastric tumors. 220
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 213
C-met inhibition blocks bone metastasis development induced by renal cancer stem cells 212
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. 190
Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals 190
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts 188
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. 187
A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy 185
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors 178
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 176
A diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells 171
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga 171
Rebound effects caused by withdrawal of MET Kinase inhibitor are quenched by a MET Therapeutic antibody 170
NOTCH3 SIGNALING REGULATES MUSASHI-1 EXPRESSION IN METASTATIC COLORECTAL CANCER CELLS. 169
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils 167
The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy 166
Inhibition of polyADP-ribosylation in cancer: Old and new paradigms revisited. 159
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth 158
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 158
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. 156
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 153
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 152
The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis 150
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 145
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. 144
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer 143
PDX-MI: Minimal information for patient-derived tumor xenograft models 141
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 132
The heme biosynthesis-heme export axis is required for the modulation of the tricarboxylic acid cycle 127
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 126
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer 124
Effective drug combinations in breast, colon and pancreatic cancer cells 124
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas 121
Differential integrin expression in thyroid and laryngeal carcinomas. 113
An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. 110
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases 110
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity 109
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 107
The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation 105
MET SIGNALING REGULATES GROWTH, REPOPULATING POTENTIAL AND BASAL CELL-FATE COMMITMENT OF MAMMARY LUMINAL PROGENITORS: IMPLICATIONS FOR BASAL-LIKE BREAST CANCER. 103
Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjögren's syndrome and gastric MALT lymphoma 102
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. 96
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 95
Implementing systems modelling and molecular imaging to predict the efficacy of BCL-2 inhibition in colorectal cancer patient-derived xenograft models 91
Interactions between scatter factors and their receptors: hints for therapeutic applications 89
Met as a potential therapeutic target in basal-like breast cancer: An in vivo approach in a stem-cell perspective 89
The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. 87
beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. 86
A membrane glycoprotein identified by the monoclonal antibody BD31 is a component of cell-cell junctions of normal and transformed epithelia. Eur J Cell Biol, 55 (Suppl 35): 54, 1991 86
A monoclonal antibody identifies a novel GPI-anchored glycoprotein involved in epithelial intercellular adhesion. 86
Negative feedback regulation of Met-dependent invasive growth by Notch 85
Adhesion molecules in squamous cell carcinoma of the larynx: possible indication of prognosis 84
Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue 83
Metabolic adaptation in colorectal cancer: heme export is required for the modulation of the tricarboxylic acid cycle. 83
A novel GPI-anchored glycoprotein shows properties of a COOH-terminus truncated cadherin involved in cell-cell contacts of cultured human epithelial cells. 81
Metabolic adaptation in colorectal cancer: heme export is required for the down-modulation of the tricarboxylic acid cycle 81
Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin 80
Altered expression of alpha 6 integrin subunit in oral squamous cell carcinoma and oral potentially malignant lesions. 80
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. 80
Animal research: Temper Italy's strict lab-animal law. 80
Met as a potential therapeutic target in basal-like breast cancer 79
Metabolic adaptation in colorectal cancer: heme export is required for the down-modulation of the tricarboxylic acid cycle. 79
Identification and pre-clinical validation of surrogate soluble biomarkers correlating with therapeutic response to met inhibition 78
Derivation and charaterization of cancer initialling cells representative of metastatic colorectal cancer genetic heterogeneity 78
Adhesion properties and integrin expression of cultured human osteoclast-like cells 77
Adhesion molecules in the control of cell proliferation and cell motility. 75
Synthetic lethality screening highlights colorectal cancer vulnerability to concomitant blockade of nedd8 and egfr pathways 75
Drug development of met inhibitors: targeting oncogene addiction and expedience 68
Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: Six degrees of separation 68
Scatter-factor and semaphorin receptors: cell signalling for invasive growth 66
MoAb BD31 DEFINES A NOVEL GPI-ANCHORED GLYCOPROTEIN CONTROLLING INTERCELLULAR-ADHESION IN NORMAL AND NEOPLASTIC EPITHELIA 66
Totale 35.218
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.497
article - articoli 0
book - libri 0
conference - conferenze 8.142
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.639
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.652 0 0 0 0 0 551 448 335 401 383 290 244
2020/20215.971 279 350 552 552 531 495 639 385 540 557 492 599
2021/20226.037 539 543 490 567 459 423 482 453 457 331 673 620
2022/20235.297 463 424 302 504 415 805 407 467 546 243 365 356
2023/20245.578 466 504 352 487 403 494 450 457 167 562 667 569
2024/20253.997 399 546 574 718 1.255 505 0 0 0 0 0 0
Totale 38.181